🌟 Novità nel campo della Ricerca Genomica 🌟
Siamo entusiasti di presentare Spatial Transcriptome Sequencing, l’espansione perfetta del consolidato portafoglio di prodotti Transcriptome Sequencing di CeGaT.
Questa metodologia all’avanguardia combina l’analisi dell’espressione genica con la morfologia tissutale, consentendo ai ricercatori di esplorare l'organizzazione spaziale delle cellule nei loro ambienti tissutali nativi.
🔍 I nostri prodotti sono disponibili in due modalità di risoluzione:
✔️ SD (Standard Definition)
✔️ HD (High Definition)
Ecco alcune aree di applicazione:
• Disturbi neurologici come l’Alzheimer: analisi della diversità e organizzazione cellulare nei tessuti cerebrali 🧠
• Ricerca sul cancro: profilazione spaziale dei tumori ed esplorazione dei microambienti tumorali 🔬
• Ematopoiesi e rigenerazione tissutale: ricostruzione di percorsi di sviluppo complessi 🧬
Scopri come il nostro Spatial Transcriptome Sequencing può spingere i confini della tua ricerca 👉 Scopri di più: https://lnkd.in/eBBtD-Kb#sequencing#transcriptome#research#science#news#STS
We are excited to introduce Spatial Transcriptome Sequencing – the perfect expansion of CeGaT's established Transcriptome Sequencing product portfolio. This cutting-edge method combines gene expression analysis with tissue morphology, allowing researchers to uncover the spatial organization of cells within their native tissue environments.
Our products are available in two resolution modes (SD and HD) and support research in areas like
• neurological disorders such as Alzheimer’s disease by uncovering cellular diversity and organization in brain tissues.
• cancer research through spatial tumor profiling and exploration of tumor microenvironments.
• hematopoiesis and tissue regeneration, enabling researchers to reconstruct complex developmental pathways.
Find out how our Spatial Transcriptome Sequencing products advance your research's boundaries: https://lnkd.in/eBBtD-Kb#sequencing#transcriptome#research#science#news#STS
Concordo come sempre con Alec Ross e aggiungo che non esiste una sola forma di #ai e #LLM ma ce ne sono tante e varie e le migliori richiedono attenzione e capacità di analisi che non tutti hanno e magari neppure sono interessati ad avere limitandosi a criticare ‘a prescindere ‘ e ad evocare catastrofi e rischi che poi sono i medesimi che anni fa accompagnarono l’#officeautomation e “‘#informatica in Europa e in Italia. Ma qui la partita è seria e dobbiamo rivedere l’affastellamento delle regole (meno male che ogni tanto si pone un problema dì ‘proporzionalità ‘ ) e le esigenze di rilanciare e migliorare i servizi pubblici e le attività private , evitando contenziosi inutili e magari approcci causidici che solo da noi si fanno strada , e ci portano a precipitare alla prima curva (altro che guard rail che qualcuno invoca) perché Cina e Stati Uniti non ci vedono nemmeno e stanno imponendo a tutti modelli (e costi) senza troppi problemi.
Co-Founder, LinkedIn & Inflection AI. Author of Superagency. Investor at Greylock.
We are closer to possible than we’ve ever been. Today, we announce the launch of Manas AI, and setting out to shift drug discovery from a decade-long process to one that takes a few years; bringing life-saving treatments to patients years faster than ever. In the beginning, our primary focus will be in oncology, developing treatments for aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma.
The promise of Artificial Intelligence is human amplification. Nobel laureates, National Academy members, and pioneering researchers who've dedicated their lives to understanding disease working hand-in-hand with advanced AI systems, exploring chemical spaces and analyzing molecular interactions at speeds 100 times faster than traditional methods. That’s what we’re building at Manas AI.
Like many of you, my co-founder Dr. Siddhartha Mukherjee and I both have had people close to us affected by cancer and other diseases. When we first discussed creating Manas AI we shared a vision of a future where breakthrough treatments don't take decades to develop. Where AI helps us explore possibilities that human researchers alone might never have time to investigate. Where technology serves as a force multiplier for human ingenuity.
While we're still in the early stages of contemporary AI development, initiatives like Manas AI show how close we already are to advances that can profoundly change the world.
Read more here https://lnkd.in/ebBwNu7H or in today’s WSJ: https://lnkd.in/eJR7xe2Y
Otto Otto Otto!!
'Near the end of his life, Warburg grew obsessed with his diet. He believed that most cancer was preventable' and Otto the Mighty WAS and IS right.
Change your lifestyle and you too can win the disease Otto Lotto 'cept the odds are stacked so heavily on your side - that I suspect that few if any will be overcome with disease through cancer transformation (/ie/ selection for unsustainable rapacious self-delusional antisocial cellular entities through encouraging biochemistry's take on greed).
Of particular interest though - the story of man - the selection for unsustainable rapacious self-delusional antisocial entities through encouraging psychology's take on greed.
Lovely - omics ('stamp collecting' - Hypothesis generation NOT testing) returns to Science (-istry and -ology).
Co-Founder, LinkedIn & Inflection AI. Author of Superagency. Investor at Greylock.
We are closer to possible than we’ve ever been. Today, we announce the launch of Manas AI, and setting out to shift drug discovery from a decade-long process to one that takes a few years; bringing life-saving treatments to patients years faster than ever. In the beginning, our primary focus will be in oncology, developing treatments for aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma.
The promise of Artificial Intelligence is human amplification. Nobel laureates, National Academy members, and pioneering researchers who've dedicated their lives to understanding disease working hand-in-hand with advanced AI systems, exploring chemical spaces and analyzing molecular interactions at speeds 100 times faster than traditional methods. That’s what we’re building at Manas AI.
Like many of you, my co-founder Dr. Siddhartha Mukherjee and I both have had people close to us affected by cancer and other diseases. When we first discussed creating Manas AI we shared a vision of a future where breakthrough treatments don't take decades to develop. Where AI helps us explore possibilities that human researchers alone might never have time to investigate. Where technology serves as a force multiplier for human ingenuity.
While we're still in the early stages of contemporary AI development, initiatives like Manas AI show how close we already are to advances that can profoundly change the world.
Read more here https://lnkd.in/ebBwNu7H or in today’s WSJ: https://lnkd.in/eJR7xe2Y
I use creativity to find new markets and solve issues I Business developer, Marketing Manager I Communication and Science enthusiast I EMBA l Mensa member
🧫🔬Una demo nel tuo lab con i tuoi campioni, si può fare ma...
devi prima contattarci, dato che il nostro super potere è la passione per ciò che facciamo, non la lettura del pensiero 🧠 +393479742823 info@m-s.it#ricerca#biotecnologia#pharma#biologia
🕵️♂️How to Get Away with a Murder in the Cellular World...
Incredible footage has captured a dramatic scene: a T-cell killing a macrophage, which is subsequently engulfed by other macrophages. This cellular "crime scene" reveals the intricate and sometimes brutal interactions within our immune system.
🧨The Cellular "Murder": T-Cell vs. Macrophage
T-cells, essential players in the adaptive immune system, are responsible for identifying and eliminating infected or abnormal cells. In this Nanolive footage, we see a T-cell targeting a macrophage. Macrophages are typically involved in engulfing pathogens and debris, but in this scenario, the T-cell has identified the macrophage as a threat and initiates its cytotoxic attack, leading to the macrophage's death.
🧫Advancements in Label-Free Live-Cell Imaging
The development of label-free imaging techniques like holotomography marks a significant advancement in cell biology. Traditional methods often rely on labels that can disrupt normal cellular functions, potentially skewing results. By contrast, Nanolive label-free imaging preserves the cells' natural behavior, providing more reliable insights into cellular interactions.
👩🔬 Implications for Research and Medicine
The insights gained from Nanolive holotomography technology extend beyond basic scientific curiosity. Understanding how immune cells interact in real time has profound implications for medical and pharmaceutical research, particularly in the fields of immunology, cancer research, and the development of immunotherapies.
Book your demo now! +393479742823 info@m-sit
#nanolive#tcell#microscopy#pharma
📑 Leggi lo studio che la Dr. Olena Kis, Direttrice di Patologia Molecolare presso l'Henry Ford Health Systems, ha presentato: "Implementing comprehensive clinical exome analysis to support diverse applications at Henry Ford Health".
🚀 Scopri come l'organizzazione Henry Ford Health ha semplificato i suoi test genetici passando da tre test separati ad un'unica potente soluzione basata sull'analisi dell'esoma, e di come SOPHiA DDM™ Exome v3 di SOPHiA GENETICS, ideale per lo studio del cancro ereditario, della fibrosi cistica e della farmacogenetica, abbia ottimizzato e consolidato i suoi flussi di lavoro,
➡️permettendo di rilevare SNV, Indel e CNV in un unico test.
Per saperne di più, leggi lo studio completo: https://lnkd.in/gKqEcSRa#HenryFordHealth#Genomics#ExomeAnalysis#GeneticTesting#DataDrivenMe
📑 Read our latest case study and testimonial from Dr. Olena Kis, Director of Molecular Pathology at Henry Ford Health Systems: "Implementing comprehensive clinical exome analysis to support diverse applications at Henry Ford Health".
🚀 Discover how Henry Ford Health streamlined its genetic testing by moving from three separate assays to a single, powerful exome-based solution.
Learn how the SOPHiA DDM™ Exome Solution v3 consolidated their workflows for hereditary cancer, cystic fibrosis, and pharmacogenetics, offering broad gene coverage with a compact assay footprint.
➡️ Dive into the full story to see how this innovative approach enabled the detection of SNVs, Indels, and CNVs in one comprehensive assay, simplifying their germline testing processes: https://lnkd.in/gKqEcSRa#HenryFordHealth#Genomics#ExomeAnalysis#GeneticTesting#DataDrivenMedicine#CustomerTestimonial
🚀 We are excited to share some of the activities from our Pathfinder Challenge #IMPACT, which aims to revolutionize how we understand and treat Arrhythmogenic Cardiomyopathy (ACM). 🧬❤️
🔍 The objectives of one of our Work Packages is to improve ACM patient stratification by determining the contribution of Variants of Unknown Significance (VUS)
🔬 Our current efforts involve:
✅ Functional classification of VUS: using cutting-edge gene editing techniques, we aim to generate allelic series of human induced pluripotent stem cells (hiPSCs) containing at least 12 VUS in PKP2, a primary gene associated with ACM.
✅ STRAIGHT-IN approach: this novel method allows us to simultaneously generate over 12 hiPSC lines with different mutations, leveraging an established control hiPSC line known for its excellent differentiation capacity and stable karyotype.
✅ In vitro cardiac organoids: since ACM manifests postnatally, we use hiPSCs to create cardiac organoids, enabling the maturation of hiPSC-derived cardiomyocytes to post-natal levels.
This comprehensive approach will enable us to classify VUS as malignant or benign more accurately than existing computational and population-based methods. 🌟
We continue to advance our understanding of ACM and work towards better, more personalized treatments. 💡🔬 Be a part of our journey and follow us! Stay tuned and visit our website https://lnkd.in/dZv23Xku for more!
AI | Dentistry | Facial Aesthetics | Marketing 👉 Coolest Doctor🦷 & Teacher in Town😉
🚨Breaking: AI can detect Breast Cancer 5 years before it develops.
Researchers from MIT have made a groundbreaking discovery that could revolutionize breast cancer detection. Their AI model can identify early signs of breast cancer up to five years before it would typically be diagnosed.
How does it work?
The AI analyzes tissue samples, looking for specific patterns in cell structure that indicate a potential risk. It's like having a crystal ball for breast health.
This breakthrough is massive because early detection is key to successful treatment.
Imagine a world where breast cancer is caught so early that it's almost like preventing the disease altogether. That’s the potential here.
Despite the skepticism around AI potentially displacing jobs, the truth is that AI holds immense promise for enhancing our lives. This is a perfect example of AI being used for good. It's a tool to save lives, to give people more time, and to change the face of healthcare.
This is just the beginning. The future of AI in medicine is incredibly exciting.
Follow me Diella Uka for more.
Join my newsletter: diellauka.substack.com#ai#medicine#healthcare#innovation
L’Intelligenza Artificiale Predice il Cancro con 5 Anni di Anticipo: Un Salto Epocale nella Diagnosi Medica
Nell’era della digitalizzazione e delle innovazioni tecnologiche, l’intelligenza artificiale (IA) continua a sorprendere e rivoluzionare diversi settori, tra cui quello della medicina. Recentemente, un’importante scoperta ha scosso il mondo della sanità: un sistema di IA è stato in grado di prevedere lo sviluppo del cancro con ben cinque anni di anticipo. Questo straordinario risultato potrebbe rappresentare un punto di svolta nella diagnosi precoce e nella lotta contro una delle malattie più temute al mondo.
La Rivoluzione dell’IA in Medicina
L’IA sta rapidamente diventando uno strumento indispensabile per i professionisti della salute. Utilizzando algoritmi avanzati e tecniche di apprendimento automatico, gli scienziati sono ora in grado di analizzare enormi quantità di dati medici con una precisione senza precedenti. Questo approccio innovativo non solo accelera il processo diagnostico, ma permette anche di individuare pattern e correlazioni che sfuggono all’occhio umano.
L’IA che Prevede il Futuro: La Scoperta
In uno studio pionieristico condotto da un team di ricercatori internazionali, è stato sviluppato un modello di IA capace di analizzare i dati genetici e clinici dei pazienti per prevedere l’insorgenza del cancro con anni di anticipo. Utilizzando dati provenienti da migliaia di casi clinici, l’algoritmo ha identificato segnali precoci e biomarcatori che indicano un alto rischio di sviluppare il cancro.
I risultati sono stati straordinari: l’IA è riuscita a predire il cancro con un’accuratezza sorprendente, spesso con un anticipo di cinque anni rispetto alle diagnosi tradizionali. Questo livello di previsione offre ai medici un vantaggio temporale cruciale per intervenire precocemente, migliorando significativamente le possibilità di trattamento e sopravvivenza dei pazienti.
Implicazioni per il Futuro della Sanità
La capacità di prevedere il cancro con tale anticipo potrebbe rivoluzionare completamente il modo in cui la medicina affronta questa malattia. Ecco alcune delle principali implicazioni:
1. Diagnosi Precoce: Con l’IA, i medici possono identificare i pazienti ad alto rischio molto prima che i sintomi diventino evidenti, permettendo interventi preventivi tempestivi.
2. Trattamenti Personalizzati: Conoscere il rischio individuale di cancro consente di sviluppare piani di trattamento personalizzati, ottimizzando le cure per ogni paziente.
3. Riduzione dei Costi Sanitari: La diagnosi precoce e i trattamenti mirati possono ridurre significativamente i costi complessivi della sanità, evitando interventi più invasivi e costosi in stadi avanzati della malattia.
4. Miglioramento della Qualità della Vita: Intervenire prima che il cancro si sviluppi o si diffonda può migliorare notevolmente la qualità della vita dei pazienti, riducendo l’impatto fisico ed emotivo della malattia.
AI | Tech | Marketing | +8 Million Followers and +1 Billion Views 👉 I will help you scale your brand and community 🏆📈
AI can predict Breast Cancer 5 years before it develops!
Researchers at MIT have developed an AI model that can identify early signs of breast cancer up to five years in advance.
This AI scans tissue samples, identifying patterns that indicate early signs of cancer, allowing for much earlier detection and treatment.
The model has been trained on tens of thousands of mammograms, allowing it to detect patterns too subtle for the human eye.
Early detection is crucial for effective treatment, and this could save countless lives by catching cancer at its earliest stages.
This won't replace doctors but it will enhance their ability to save lives by offering more precise risk assessments and early interventions.
This is just the beginning. The potential of AI in medicine is vast, and we're only scratching the surface of how it can revolutionize healthcare, finding new cures and saving lives in ways we couldn't before.
Follow me Endrit Restelica for more tech stuff.
#ai#tech#medicine#healthcare#innovation
Unisciti a Campoverde per un entusiasmante Webinar il 14 Novembre con esperti dell'Allen institute for Immunology e scoprire nuovi mezzi per comprendere meglio i percorsi molecolari e i meccanismi coinvolti nelle patologie immuno-mediate.
Join our webinar on Nov 14th with speakers from the Allen Institute for Immunology. They use a full spectrum of -omics tools to understand the molecular pathways and mechanisms responsible for the progression of immune-driven pathology. https://bit.ly/48ieTFI
💡 Scopri la piattaforma DDM™ SOPHiA di SOPHiA GENETICS.
Perché scegliere la piattaforma SOPHiA DDM™ per l'analisi dell'esoma?
Þ Possibilità di analizzare e caratterizzare le varianti genetiche, trasformando i dati complessi dell'esoma in informazioni clinicamente rilevanti.
Þ Soluzioni all-in-one per flussi di lavoro clinici, utile in ambiti come malattie rare, tumori ereditari e farmacogenomica.
Þ Piattaforma informatica indipendente dalla tecnologia, compatibile con qualsiasi metodo di sequenziamento e arricchimento dell'esoma.
Þ Integrazione con partner certificati per l'analisi e la reportistica sicura dei dati
🔗 Esplora la potenza della piattaforma DDM™ SOPHiA per l'analisi dell'esoma: https://lnkd.in/gY585wtp
💡 The SOPHiA DDM™ Platform reliably calls and prioritizes variants, turning complex and noisy genomic data sets from exome sequencing into valuable insights for data-driven decision-making.
Why choose the SOPHiA DDM™ Platform for exome analysis?
➡ All-in-one solution: Consolidate your workflows with the SOPHiA DDMTM Clinical and Whole Exome Solutions, with rare disease, hereditary cancer, and Pharmacogenomics applications and more!
➡ Universal: The SOPHiA DDM™ Platform is technology-agnostic for simple integration into existing workflows with any top exome enrichment chemistry, emerging sequencers, and liquid handlers.
➡ Integrated: SOPHiA DDM™ Integrated Access Mode lets you tap into certified sequencing partners who generate sequencing data and securely upload it to your SOPHiA DDM™ account for analysis and reporting, while you maintain full ownership of all data.
➡ Enhanced Tertiary Capabilities: Advanced filtering and AI-powered variant prioritization
Interested to know more?
🔗 Explore the power of the SOPHiA DDM™ Platform for exome analysis: https://lnkd.in/gY585wtp#DataDrivenMedicine#ExomeAnalysis#AIforHealthcare
